Biodexa Pharmaceuticals PLC (BDRX) Says eRapa Phase 3 Is Over 50% Enrolled; Futility Read in Q1 2027

Biodexa Pharmaceuticals PLC reported its Phase 3 eRapa trial in FAP is over 50% enrolled across 29 U.S./EU centers, with an interim futility analysis expected in Q1 2027. The program has FDA/EMA Orphan Drug status and $20M CPRIT grant support.Material DetailsContext by AI AnalystThis is an executio…